Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin + BEAM Conditioning for Autologous Stem Cell Transplant in Refractory DLBCL
NCT00646750Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jan 2008
- Primary completion
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by GELTAMO. Primary endpoint: Complete Response Rate. Started Jan 2008; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00646750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646750.